The FDA-approved indication for semaglutide in weight management applies to adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or heart disease
Studies published in peer-reviewed journals show consistent reductions in visceral fat mass over 1252 weeks of treatment
Accessed June 9, 2026.
It also comes on the heels of the brand's Lemme Curb, $30, chew launch, a new format in the lineup
Pigmentation and Scar Reduction It minimizes acne scars, melasma, age spots, and sun damage, giving a flawless and smooth skin appearance
Supports bone and connective tissue wellness